Lung Transplant Rejection Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE. The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE. For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06309628 -
Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
|
||
| Withdrawn |
NCT02893176 -
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
|
Phase 4 | |
| Completed |
NCT02441413 -
Transplant Optimization Using Functional Imaging (TROFI)
|
N/A | |
| Recruiting |
NCT05375149 -
Exhaled Breath Particles in Lung Transplantation
|
||
| Active, not recruiting |
NCT03967340 -
PREdiction of Chronic LUng Allograft Dysfunction
|
||
| Active, not recruiting |
NCT05260372 -
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
|
||
| Recruiting |
NCT04714801 -
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05170425 -
LAMBDA 002 (Lung Registry) Study
|
||
| Completed |
NCT02474927 -
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
|
Phase 2 | |
| Recruiting |
NCT05006742 -
Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients
|
N/A | |
| Recruiting |
NCT02812290 -
Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
|
||
| Not yet recruiting |
NCT03500575 -
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
|
N/A | |
| Withdrawn |
NCT03805178 -
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
|
Phase 2 | |
| Completed |
NCT03359863 -
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
|
Phase 2 | |
| Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
| Completed |
NCT01985412 -
Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
|
||
| Completed |
NCT04234919 -
Longitudinal Study of Cell Free DNA in Lung Transplant
|
||
| Recruiting |
NCT04837339 -
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
|
N/A | |
| Recruiting |
NCT03090581 -
Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.
|
N/A | |
| Recruiting |
NCT06112951 -
A Prospective Randomized Trial of ECP in Subclinical AMR
|
N/A |